CagriSema beats tirzepatide on weight loss in phase 3 diabetes trial
Novo Nordisk says it will now align a regulatory pathway for the type 2 diabetes indication after results published 21 September.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 27 02:40 ETSource: AD HOC NEWS
The wire
- 01Phase 3 results published 21 September showed CagriSema produced 12.4% average weight loss over roughly 60 weeks in adults with type 2 diabetes versus 9.1% for tirzepatide; a separate trial in overweight patients reached 21% reduction against control.
- 02A head-to-head edge over tirzepatide is the metric payers and prescribers will use when CagriSema reaches the market alongside existing incretins.
- 03The roughly three-point margin still has to survive regulatory review and tolerability scrutiny; CEO Mike Doustdar separately told Reuters oral obesity drugs could take half the global market by 2030.
From the source
Read at ad-hoc-news.deNovo Nordisk Bets on Pills and Partnerships as CagriSema Data Faces Regulatory Test
Novo Nordisk's leadership believes the future of obesity treatment will increasingly be swallowed, not injected. CEO Mike Doustdar told Reuters on Tuesday that oral medications could capture as much as half of the global market for obesity drugs by 2030 — a projection that underpins a widening push by the Danish drugmaker into novel delivery formats.
